EU expands use of Roche's Pegasys in chronic hepatitis C
ZURICH (Reuters) - Roche said on Monday the European Medicines Agency (EMA) has expanded the approval of its drug Pegasys plus ribavirin for the treatment of chronic hepatitis C virus (HCV) to children five years of age and older.
The new label for the medicine that was first approved in the European Union over 10 years ago includes children five years and older who have not received treatment and have tested positive for HCV, Roche said in a statement.
Pegasys, in combination with the antiviral ribavirin, is the foundation of treatment for chronic HCV in adults, Roche said.
Mother-to-child transmission of HCV is the most common route of acquiring the infection in children with approximately 65,000 children estimated to live with chronic HCV in Europe, Roche said.
(Reporting by Silke Koltrowitz)
- Gaza fighting abates as diplomatic tension flares |
- Hague court orders Russia to pay over $50 billion in Yukos case
- Man found dead trapped between elevator and shaft wall in NYC
- Europe nervy as Russian assets hit by new sanctions talk
- Ukraine troops advance as experts renew attempt to reach crash site
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video